TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28283823

Group type: EXPERIMENTAL
Intervention: Freeze-dried blueberry (24 g/day, equivalent to 1 cup of fresh blueberries) for 90 days
Number of subjects: 37

Group type: COMPARATOR
Intervention: Blueberry placebo
Number of subjects: 37
Study: 26968101

Group type: EXPERIMENTAL
Intervention: Korean CKD-EPI equation
Number of subjects: 960

Group type: COMPARATOR
Intervention: Original CKD-EPI equation
Number of subjects: 960
Study: 24793893

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA) 3 g
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (no TXA)
Number of subjects: 101
Study: 22817667

Group type: EXPERIMENTAL
Intervention: Erlotinib followed by chemotherapy after progression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy followed by erlotinib after progression
Number of subjects: 0
Study: 19454124

Group type: EXPERIMENTAL
Intervention: Antenatal micronutrient supplementation
Number of subjects: 4096
Study: 17392439

Group type: EXPERIMENTAL
Intervention: Presence of the rrgC gene in vaccine-type strains
Number of subjects: 100

Group type: COMPARATOR
Intervention: Frequency of rrgC in isolates before and after 2000
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Concordance of multilocus sequence types with rrgC presence
Number of subjects: 100
Study: 16305317

Group type: EXPERIMENTAL
Intervention: Whiplash patients (WAD)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Whiplash patients with head/neck turned at collision
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Front collisions
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control persons
Number of subjects: 92
Study: 11895146

Group type: EXPERIMENTAL
Intervention: TPN with fish oil (0.2 g/kg body weight per day) plus soybean oil (1.0 g/kg per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Soybean oil (1.2 g/kg per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fat-free regimen
Number of subjects: 60
Study: 9751068

Group type: EXPERIMENTAL
Intervention: 400 microg salbutamol via diskhalers
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 microg salbutamol via diskhalers
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 microg salbutamol via metered-dose inhalers (MDIs)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7917690

Group type: EXPERIMENTAL
Intervention: Electrical cardioversion
Number of subjects: 63
Study: 3289831

Group type: EXPERIMENTAL
Intervention: 0.5 mg lormetazepam
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: 1.0 mg lormetazepam
Number of subjects: 145
Study: 29624601

Group type: EXPERIMENTAL
Intervention: AP scan® measurements
Number of subjects: 41
Study: 27152103

Group type: EXPERIMENTAL
Intervention: Acute oral administration of 250 mL of mangosteen-based juice (305 mg of α-mangostin and 278 mg of hydroxycitric acid)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (control treatment)
Number of subjects: 12
Study: 25621927

Group type: EXPERIMENTAL
Intervention: Family therapy (MDFT)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Group therapy (AGT)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both treatments (MDFT and AGT)
Number of subjects: 112
Study: 23240743

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 100
Study: 21676054

Group type: EXPERIMENTAL
Intervention: Enhanced care (brochure, motivational interview, nicotine patches, phone call at 3 days)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Usual care (smoking cessation brochure)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Enhanced care
Number of subjects: 338

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 338
Study: 18652324

Group type: EXPERIMENTAL
Intervention: Acupoint injection of botulinum toxin type A (BTX‐A) into tender points at the third lumbar transverse process or surrounding acupoints.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Acupuncture at the same points as in the acupoint-injection group.
Number of subjects: 25
Study: 17035442

Group type: EXPERIMENTAL
Intervention: Rollator use
Number of subjects: 31
Study: 12932433

Group type: EXPERIMENTAL
Intervention: Glucose (50 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (27.3 mg saccharin)
Number of subjects: 0
Study: 10789026

Group type: EXPERIMENTAL
Intervention: Imaginal exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive therapy
Number of subjects: 0
Study: 9097873

Group type: EXPERIMENTAL
Intervention: m‐CPP (0.5 mg/kg of body weight)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 8040669

Group type: EXPERIMENTAL
Intervention: High-dose IL-2 (720,000 IU/kg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Low-dose IL-2 (72,000 IU/kg)
Number of subjects: 125
Study: 2923686

Group type: EXPERIMENTAL
Intervention: Cefazolin sodium
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 4880407

Group type: EXPERIMENTAL
Intervention: Iron preparation 1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Iron preparation 2
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 30
Study: 31744312

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care sedation
Number of subjects: 0
Study: 31196776

Group type: EXPERIMENTAL
Intervention: Pharmacist's educational intervention
Number of subjects: 450
Study: 28807019

Group type: EXPERIMENTAL
Intervention: Antenatal syphilis screening and treatment intervention (details on dosage and duration not available)
Number of subjects: 112
Study: 24700992

Group type: COMPARATOR
Intervention: Bypassers (women who bypassed local primary care clinics for childbirth)
Number of subjects: 3019

Group type: EXPERIMENTAL
Intervention: Women who delivered in a health facility (non-bypassers)
Number of subjects: 3019

Group type: COMPARATOR
Intervention: Women who perceived poor quality at clinics
Number of subjects: 3019

Group type: COMPARATOR
Intervention: Women who delivered at clinics that recently underwent renovations
Number of subjects: 3019

Group type: COMPARATOR
Intervention: Women who delivered at clinics performing ≥ 4 obstetric signal functions
Number of subjects: 3019

Group type: COMPARATOR
Intervention: Primiparous women (first-time mothers)
Number of subjects: 3019
Study: 22381427

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) treatment
Number of subjects: 884
Study: 20473071

Group type: EXPERIMENTAL
Intervention: Physical health recommendations and nonspecific interactions with study patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive, behavioral, and emotionally supportive interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investigator's personal experiences and siding with the patient on interpersonal conflicts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time spent with patients at midstudy visits
Number of subjects: 0
Study: 17667193

Group type: EXPERIMENTAL
Intervention: Self-management program (group 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 50
Study: 16181595

Group type: EXPERIMENTAL
Intervention: Mental Imagery (MI) and Kinesiology (KG)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Kinesiology (KG) alone
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (Advandec Trauma Life Support - ATLS)
Number of subjects: 44
Study: 11874395

Group type: EXPERIMENTAL
Intervention: Activated charcoal after 1 h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gastric lavage followed by activated charcoal after 1 h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Activated charcoal after 2 h
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 12
Study: 10402370

Group type: EXPERIMENTAL
Intervention: Puregon(R)Pen
Number of subjects: 22

Group type: COMPARATOR
Intervention: Syringe
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 22
Study: 7992934

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.30 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine (10 mg)
Number of subjects: 0
Study: 2675669

Group type: EXPERIMENTAL
Intervention: Lipid emulsion formulation of etomidate
Number of subjects: 16

Group type: COMPARATOR
Intervention: Propylene glycol formulation of etomidate (Hypnomidate)
Number of subjects: 16
Study: 1253812

Group type: EXPERIMENTAL
Intervention: Fructose administered simultaneously with ethanol
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Glucose administered simultaneously with ethanol
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Fructose administered 12 hours later during the hangover period
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Glucose administered 12 hours later during the hangover period
Number of subjects: 109

Group type: COMPARATOR
Intervention: Ethanol only (control group)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Comparison of fructose and glucose
Number of subjects: 109
Study: 31786715

Group type: EXPERIMENTAL
Intervention: Tetanic prestimulation (50 Hz for 5 s)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No tetanic prestimulation (control)
Number of subjects: 80
Study: 31533195

Group type: EXPERIMENTAL
Intervention: Phylloquinone supplementation
Number of subjects: 151
Study: 29042490

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham ischemia-reperfusion cycles
Number of subjects: 30
Study: 26252642

Group type: EXPERIMENTAL
Intervention: Milk post exercise
Number of subjects: 54

Group type: COMPARATOR
Intervention: Carbohydrate beverage (CONT)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54
Study: 22986418

Group type: EXPERIMENTAL
Intervention: 8% sevoflurane in N(2)O 4 litre min(‐1) and O(2) 2 litre min(‐1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 8% sevoflurane in O(2) 6 litre min(‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: N(2)O
Number of subjects: 80
Study: 22071711

Group type: EXPERIMENTAL
Intervention: Palm olein
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lard
Number of subjects: 32

Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 32
Study: 19893201

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) treatment
Number of subjects: 0
Study: 17111195

Group type: EXPERIMENTAL
Intervention: Thrombolysis with ultra-high dose streptokinase (n = 8)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Thrombolysis with alteplase (tPA) (n = 7)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Thrombolysis (combined results)
Number of subjects: 15
Study: 15317270

Group type: EXPERIMENTAL
Intervention: Parietaria pollen vaccine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Matched placebo injections
Number of subjects: 30
Study: 10668686

Group type: EXPERIMENTAL
Intervention: Unopposed conjugated equine estrogens (1.25 mg/day) for 16 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 9061102

Group type: EXPERIMENTAL
Intervention: Oxycodone (20 mg or 40 mg oral controlled-release tablet)
Number of subjects: 98
Study: 8227788

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 20
Study: 3021324

Group type: EXPERIMENTAL
Intervention: Sulpiride (600 mg intramuscularly in a single administration, followed by 200 mg 3 times per day from days 2-21, then 100 mg and 50 mg 3 times per day on days 22-25 and 26-29, respectively)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo (control group of 10 heroin addicts)
Number of subjects: 410
Study: 30021580

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) at 60 seconds
Number of subjects: 113

Group type: COMPARATOR
Intervention: Early cord clamping (ECC) immediately after birth
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) and Early cord clamping (ECC)
Number of subjects: 113
Study: 27540883

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 949
Study: 24434302

Group type: EXPERIMENTAL
Intervention: Autologous reinfusion by cell saver or DRAIN
Number of subjects: 1759

Group type: COMPARATOR
Intervention: No blood salvage device (Control)
Number of subjects: 1759
Study: 22037130

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD)
Number of subjects: 37
Study: 20188175

Group type: EXPERIMENTAL
Intervention: M01ZH09 (typhoid vaccine)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 17942447

Group type: EXPERIMENTAL
Intervention: Training intervention for on-site, in-charge reproductive health supervisors
Number of subjects: 60
Study: 16330302

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori test-and-treat strategy
Number of subjects: 223

Group type: COMPARATOR
Intervention: Prompt endoscopy
Number of subjects: 223
Study: 15071265

Group type: EXPERIMENTAL
Intervention: AAIR pacing
Number of subjects: 0

Group type: COMPARATOR
Intervention: VVI(R) pacing
Number of subjects: 0

Group type: COMPARATOR
Intervention: DDDR pacing
Number of subjects: 0
Study: 10222388

Group type: EXPERIMENTAL
Intervention: Standard infant formula (HP group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recommended dietary regimen (LP group)
Number of subjects: 0
Study: 8902444

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose complex (ISC)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Ferrous sulfate (control)
Number of subjects: 111
Study: 1725547

Group type: EXPERIMENTAL
Intervention: Intracoronary diltiazem (500 micrograms i.c. bolus)
Number of subjects: 25
Study: 6357036

Group type: EXPERIMENTAL
Intervention: Topical povidone‐iodine spray in addition to a single dose of intravenous metronidazole
Number of subjects: 200

Group type: COMPARATOR
Intervention: Single dose of intravenous metronidazole
Number of subjects: 200
Study: 31440235

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Corticosteroid (CS) treatment
Number of subjects: 0
Study: 28682676

Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT) (635 nm)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 27531014

Group type: EXPERIMENTAL
Intervention: High level of physical activity (5-7 times per week)
Number of subjects: 1569

Group type: COMPARATOR
Intervention: Low level of physical activity (1-2 times per week)
Number of subjects: 1569
Study: 25902655

Group type: EXPERIMENTAL
Intervention: Perindopril 5‐10 mg/day + Indapamide retard 1.5 mg/day (P+I)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Perindopril 5‐10 mg/day + Hydrochlorothiazide 25 mg/day (P+HT)
Number of subjects: 40
Study: 21536813

Group type: EXPERIMENTAL
Intervention: Pre-notification letter
Number of subjects: 59953

Group type: EXPERIMENTAL
Intervention: Pre-notification letter + information booklet
Number of subjects: 59953

Group type: COMPARATOR
Intervention: Usual invitation
Number of subjects: 59953
Study: 19675482

Group type: EXPERIMENTAL
Intervention: Graduated compression tights (CG)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Passive recovery (CON)
Number of subjects: 11
Study: 18705444

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA) with spontaneous ventilation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Endotracheal tube (ETT) with intermittent positive pressure ventilation (IPPV)
Number of subjects: 100
Study: 15510982

Group type: EXPERIMENTAL
Intervention: rHuEPO (5000 U/day subcutaneously three times a week) until three weeks after chemotherapy completion in Groups 1, 2A, and 3A
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: rHuEPO for 12 weeks in Groups 2B and 3B
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: rHuEPO usage strategies
Number of subjects: 77
Study: 11304102

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 9287

Group type: COMPARATOR
Intervention: No Ramipril (Control)
Number of subjects: 9287

Group type: EXPERIMENTAL
Intervention: Renal insufficiency
Number of subjects: 9287
Study: 9187888

Group type: EXPERIMENTAL
Intervention: Hormone therapy with a combination of oestrogen and progesterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional management (surgical resection and endoscopic fulguration)
Number of subjects: 0
Study: 7945738

Group type: EXPERIMENTAL
Intervention: 20 mg cocaine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 40 mg cocaine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 3605793

Group type: EXPERIMENTAL
Intervention: fenoterol nebulized by facial mask
Number of subjects: 150

Group type: COMPARATOR
Intervention: epinephrine by subcutaneous injection
Number of subjects: 150
Study: 29655928

Group type: EXPERIMENTAL
Intervention: Sitting callisthenic balance (SCB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance exercise (RET)
Number of subjects: 0
Study: 27621249

Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided stellate ganglion blockade (SGB)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 36
Study: 24841321

Group type: EXPERIMENTAL
Intervention: Avonex
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Rebif
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Betaferon
Number of subjects: 90
Study: 22925609

Group type: EXPERIMENTAL
Intervention: Manual therapy (MT) plus active exercises (AE)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham therapy (ST) plus active exercises (AE)
Number of subjects: 42
Study: 20456826

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate cream formulations (0.05%)
Number of subjects: 0
Study: 18667647

Group type: EXPERIMENTAL
Intervention: Ethics consultation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomised controlled trials
Number of subjects: 0
Study: 15975493

Group type: COMPARATOR
Intervention: Control (C; 480 mL of a study beverage containing 82 g of carbohydrate, 20 g of protein, and 14 g of fat)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Control plus 3.5 g each of phenylalanine and leucine (AA)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Control plus 1000 mg of S. oblonga extract (S)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Control plus S and AA (SAA)
Number of subjects: 43
Study: 11834946

Group type: EXPERIMENTAL
Intervention: ARV therapy (protease inhibitors: ritonavir, nelfinavir, or lopinavir/ritonavir)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ARV therapy (ritonavir)
Number of subjects: 15

Group type: COMPARATOR
Intervention: ARV therapy (zidovudine)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ARV therapy
Number of subjects: 15
Study: 10351853

Group type: EXPERIMENTAL
Intervention: Staged-based message intervention
Number of subjects: 527

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 527
Study: 7747844

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl 25 micrograms.h‐1
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl 50 micrograms.h‐1
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl 75 micrograms.h‐1
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 2406849

Group type: EXPERIMENTAL
Intervention: 0.125 mg triazolam
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 6996635

Group type: EXPERIMENTAL
Intervention: Injectable heroin
Number of subjects: 96

Group type: COMPARATOR
Intervention: Oral methadone
Number of subjects: 96

Group type: COMPARATOR
Intervention: Refusal to prescribe heroin
Number of subjects: 96
Study: 30578850

Group type: EXPERIMENTAL
Intervention: Home visitation program with obesity prevention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard home visitation program
Number of subjects: 300
Study: 28793993

Group type: EXPERIMENTAL
Intervention: Taurolidine-citrate-heparin lock
Number of subjects: 41

Group type: COMPARATOR
Intervention: Heparin 100 IE/mL
Number of subjects: 41
Study: 25749825

Group type: EXPERIMENTAL
Intervention: Intrathecal liposomal cytarabine (50 mg: 6/8 injections)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Intrathecal triple therapy (methotrexate/cytarabine/prednisone: 12 injections)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Intrathecal liposomal cytarabine (50 mg)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Intrathecal triple therapy
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Intrathecal liposomal cytarabine
Number of subjects: 145
Study: 23406078

Group type: EXPERIMENTAL
Intervention: 2 mg intravenous hydromorphone
Number of subjects: 175

Group type: COMPARATOR
Intervention: Usual care (any IV opioid as chosen by ED attending)
Number of subjects: 175
Study: 21211865

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy Follow‐Up (PFU) and health education
Number of subjects: 87

Group type: COMPARATOR
Intervention: Health education only
Number of subjects: 87
Study: 18810305

Group type: EXPERIMENTAL
Intervention: Lectures and peer coaching
Number of subjects: 0
Study: 16083782

Group type: EXPERIMENTAL
Intervention: 250 microg of oral roflumilast
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 500 microg of oral roflumilast
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 12218518

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia with bupivacaine and fentanyl
Number of subjects: 64

Group type: COMPARATOR
Intervention: Patient-controlled analgesia with morphine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study: 10504889

Group type: EXPERIMENTAL
Intervention: Lifting at slowest speed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifting at slow speed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifting at normal speed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifting at fast speed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifting at fastest speed
Number of subjects: 0